- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04068805
Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
July 15, 2022 updated by: Happify Inc.
Participants will be randomly assigned to either a positive affect skills intervention or a psychoeducation control group and assessed with questionnaires before, during, and after the 8-week program, as well as at 3 months, 6 months, and 12 months after the end of the program.
Study Overview
Detailed Description
Participants will be randomly assigned to either the Diabetes positive affect skills intervention or a psychoeducation control group.
Both programs last 8 weeks and take place on a simplified research version of the Happify platform.
Participants assigned to the diabetes positive affect program will have full access to Happify, with a track that focuses on building skills for greater happiness, reducing stress, and coping better with diabetes displayed as the feature track.
Participants assigned to the psychoeducation (control) condition will be asked to complete a series of polls on various wellbeing topics, and then provided with some social comparison data about how their responses compared with the responses of other users, as well as information about why the well being topic is important.
Participants will be asked to complete questionnaires before, during, and after the 8-week program as well as 3 months, 6 months and 12 months follow-up questionnaires after the program is complete, at which point study participation will end.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10012
- Happify (an online platform -- study is entirely online)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults with Type 2 Diabetes
- Elevated HbA1c levels (7 or greater)
- No prior experience on the Happify platform (new user registration)
- PHQ-8 score of 13 or higher
- US resident
- Under the care of a medical professional for the treatment of their diabetes
- Be willing and able to obtain HbA1c every 3 months
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Positive affect condition
Participants use Happify and have the option to use a diabetes-specific track that focuses on building skills for greater happiness, reducing stress, and coping better with diabetes.
Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
|
An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
|
Sham Comparator: Psychoeducation condition
Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being.
Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
|
An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in self-reported HbA1C level
Time Frame: Baseline, 3 weeks post-intervention (day 83), 3 weeks after 3-month post intervention (day 173), 3 weeks after 6 month post intervention (day 263), and 12 months post intervention (day 416)
|
1-item self-reported measure of Hemoglobin A1C (HbA1C) level, "What was your most recent HbA1c level?"
|
Baseline, 3 weeks post-intervention (day 83), 3 weeks after 3-month post intervention (day 173), 3 weeks after 6 month post intervention (day 263), and 12 months post intervention (day 416)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Depression symptoms [PHQ-9 questionnaire]
Time Frame: Baseline, immediate post-intervention at 8 weeks, and at 3, 6, and 12 months post-intervention
|
9-item measure of depressive symptoms scoring how often the participant has been bothered by each statement over the past 2 weeks from not at all (0) to nearly every day (3).
|
Baseline, immediate post-intervention at 8 weeks, and at 3, 6, and 12 months post-intervention
|
Change in Diabetes Regimen Adherence
Time Frame: From baseline up to 63 days, 7 days at 3 months post intervention (146-153), 7 days at 6 months post intervention (236-243), and 12 months post intervention (day 416-423)
|
1-item measure on keeping up with diabetes regimen in the past 24 hours, asking "Which of the following activities in your diabetes regimen did you complete over the past 24 hours?"
|
From baseline up to 63 days, 7 days at 3 months post intervention (146-153), 7 days at 6 months post intervention (236-243), and 12 months post intervention (day 416-423)
|
Change in Perceived Stress [Perceived Stress Scale (PSS)]
Time Frame: Baseline, immediate post-intervention at 8 weeks, and at 3, 6, and 12 months post-intervention
|
10-item measure of perceived stress scoring how often the participant felt stressed by each statement in the following month from never (0) to very often (4).
|
Baseline, immediate post-intervention at 8 weeks, and at 3, 6, and 12 months post-intervention
|
Change in diabetes self-care activities [Summary of Diabetes Self-Care Activities (SDSCA)]
Time Frame: Baseline, immediate post-intervention at 8 weeks, and at 3, 6, and 12 months post-intervention
|
11-item measure of self-reported adherence to diabetes self-care activities, ex.
"On how many of the last seven days did you participate in at least 30 minutes of physical activity?" with possible answers of 0 to 7 days for each question.
|
Baseline, immediate post-intervention at 8 weeks, and at 3, 6, and 12 months post-intervention
|
Change in positive affect [Patient-Reported Outcomes Measurement Information Systems - Positive Affect Subscale(PROMIS)]
Time Frame: Baseline, immediate post-intervention at 8 weeks, and at 3, 6, and 12 months post-intervention
|
15-item measure of positive affect scoring participants on how often then felt each statement was true over the past 7 days from not at all (1) to very much (5)
|
Baseline, immediate post-intervention at 8 weeks, and at 3, 6, and 12 months post-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 31, 2020
Primary Completion (Actual)
April 1, 2021
Study Completion (Actual)
July 12, 2022
Study Registration Dates
First Submitted
August 23, 2019
First Submitted That Met QC Criteria
August 23, 2019
First Posted (Actual)
August 28, 2019
Study Record Updates
Last Update Posted (Actual)
July 19, 2022
Last Update Submitted That Met QC Criteria
July 15, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Happify
-
Happify Inc.CompletedPsychological Distress | LonelinessUnited States
-
Happify Inc.CompletedWell-beingUnited States
-
Happify Inc.Completed
-
Donna SchumanUniversity of Kentucky; Happify Inc.Withdrawn